BRUSSELS, Feb 10 (Reuters) - EU antitrust regulators accepted on Wednesday South African pharmaceutical company Aspen’s offer to cut the prices of six cancer drugs by 73% and to set a 10-year price cap in return for ending a three-year long investigation that could have resulted in a hefty fine.
The European Commission said Aspen will also guarantee the supply of the medicines for the next five years, confirming a Reuters report on Feb. 3.
The medicine is used to treat certain serious forms of blood cancer, including myeloma and leukaemia. (Reporting by Foo Yun Chee)
Our Standards: The Thomson Reuters Trust Principles.